AVTX- Avalo Therapeutics, Inc.

Name: Avalo Therapeutics, Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

Avalo Therapeutics, Inc. (AVTX) has 9 insiders with recent SEC Form 4 filings, including 17 buys and 0 sells. AVTX is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
Other	Boyd Taylor	275.0K	$4.04M	-
Other	Doyle Mittie	47.8K	$702.7K	-679
CFO	Sullivan Christopher Ryan	19.1K	$281.0K	-
Other	Varki Paul	3.6K	$53.4K	-
Dir	Chan Mitchell	3.2K	$46.5K	-

Activity

Buys and sells only

Transactions

10 filings · page 5

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Jun 10, 2021	Neil Garry Arthur	Chief Scientific Officer	Buy	3,692	$2.28	$8,417.76	+4.8%	-22.9%	-87.0%
Jun 10, 2021	Greenway Schond L.	CFO	Buy	652	$2.68	$1,747.36	+65.2%	-22.9%	-87.0%
Jun 10, 2021	Harrell James Archie Jr	Chief Commercial Officer	Buy	7,493	$2.28	$17,084.04	+26.6%	-22.9%	-87.0%
Jun 10, 2021	Wilkins H Jeffrey	Chief Medical Officer	Buy	912	$2.28	$2,079.36	+3.5%	-22.9%	-87.0%
May 18, 2021	Armistice Capital, LLC56	Director, 10% Owner	Buy	180,000	$2.18	$392,460.00	-	+22.0%	-85.6%
Jan 8, 2021	Armistice Capital, LLC56	Director, 10% Owner	Buy	2,500,000	$2.60	$6,500,000.00	+4.0%	-	-
Dec 10, 2020	Harrell James Archie Jr	Chief Commercial Officer	Buy	171	$2.28	$389.54	+0.6%	-	-
Dec 10, 2020	Sullivan Christopher Ryan	Interim CFO	Buy	5,095	$2.28	$11,606.41	+172.5%	-	-
Dec 10, 2020	Neil Garry Arthur	Chief Scientific Officer	Buy	3,599	$2.28	$8,198.52	+4.9%	-	-
Dec 3, 2020	Armistice Capital, LLC56	Director, 10% Owner	Buy	20,000	$2.44	$48,800.00	-	-	-

← PrevPage 5Next →

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC